Highest-materiality recent filing
All 10 director nominees elected; CEO Reshma Kewalramani received ~221.9M votes.
Total revenue $2.99B, up 8% vs Q1 2025; GAAP net income $1.0B, non-GAAP $1.1B.
Vertex director Suketu Upadhyay to depart after annual meeting to become Incyte CFO
Upadhyay will not stand for re-election due to scheduling conflicts from his incoming CFO role at Incyte.
Vertex completes BLA submission for povetacicept in IgAN with priority review
Submitted rolling Biologics Licensing Application to FDA for povetacicept to treat IgAN in adults.
Vertex reports FY2025 revenue $12.0B (+9% YoY); guides FY2026 revenue $12.95-13.1B
FY2025 total revenue $12.0B, up 9% YoY; Q4 revenue $3.19B, up 10% YoY.
Vertex Q3 rev $3.08B (+11% YoY), FY guidance refined; povetacicept IgAN BLA on track
Q3 total revenue $3.08B (+11% vs Q3 2024); GAAP net income $1.1B, non-GAAP $1.2B.
Vertex Q2 revenue $2.96B (+12% YoY); CSO Altshuler to retire Aug 2026; Bunnage to succeed
Q2 revenue $2.96B (+12% YoY); GAAP net income $1.0B vs loss $3.6B last yr; non-GAAP net income $1.2B vs loss $3.3B
Vertex Pharmaceuticals authorizes $4.0B share repurchase program
Board authorized new $4.0B stock repurchase program (2025 Repurchase Program) with no expiration date.
Vertex shareholders elect all 11 directors, reject golden parachute proposal at 2025 annual meeting
All 11 director nominees elected with majority support; Bruce Sachs received lowest 'for' votes at 211.6M.
Revenue $2.77B, +3% YoY; US revenue +9% to $1.66B, ex-US -5% to $1.11B due to Russia IP violation.
Vertex halts VX-264 type 1 diabetes program; expects ~$400M impairment charge
Phase 1/2 trial of VX-264 for type 1 diabetes fails; program will not advance further.
Q4 product revenue $2.91B (+16% YoY); full-year product revenue $11.02B (+12%) driven by TRIKAFTA/KAFTRIO.
Vertex receives FDA approval for new CF drug ALYFTREK; wholesale cost $370K/year
FDA approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for CF in patients 6+ years with at least one F508del mutation.
Vertex Q3 product revenue $2.77B (+12% YoY); raises FY guidance to $10.8-10.9B
GAAP net income $1.0B; non-GAAP net income $1.1B; cash & securities $11.2B.
Vertex extends Boston headquarters leases to 2044, adding renewal options
Extended combined ~1.1 million sq ft of office and lab space under two leases in Boston.
Vertex Q2 product revenue $2.65B (+6% YoY); raises FY 2024 guidance to $10.65-10.85B
GAAP net loss of $3.6B in Q2 due to $4.4B AIPR&D charge from Alpine acquisition.
Vertex expects $4.4B AIPR&D charge and $200M compensation expense from Alpine acquisition in Q2 2024
Vertex records one-time non-deductible AIPR&D expense of approx. $4.4B in Q2 2024 from Alpine asset acquisition accounting.
Vertex completes $5.0B acquisition of Alpine Immune Sciences on May 20, 2024
Acquisition of Alpine for approximately $5.0B in equity value completed.
Vertex Pharmaceuticals Shareholders Elect Directors and Approve Proposals at Annual Meeting
Shareholders elected all 11 board nominees, including Reshma Kewalramani and Jeffrey Leiden, with each receiving over 217 million votes for.
Vertex Q1 product revenue $2.69B (+13% YoY); reiterates FY guidance; $4.9B Alpine acquisition
Q1 product revenue $2.69B, up 13% YoY; GAAP net income up 57%; Non-GAAP net income up 56%.
Suketu Upadhyay informed the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the "2026 Annual Meeting").
the appointment of Duncan J. McKechnie as Chief Commercial Officer of the Company
The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer of the Company
On February 10, 2025, Vertex Pharmaceuticals Incorporated (the “Company”) announced the retirement of Stuart A. Arbuckle, the Company’s Executive Vice President and Chief Operating Officer, effective on July 1, 2025.
Max materiality 0.85 · Median 0.72 · Most common event earnings